-
公开(公告)号：EP1355942B1
公开(公告)日：2008-08-27
申请号：EP01995845.3
申请日：2001-11-29
IPC分类号： C07K14/605 , C07K14/765 , C12N15/62 , A61K38/38 , A61K38/26 , C07K19/00 , A61P3/10
CPC分类号： C07H21/04 , A61K38/00 , C07K14/605 , C07K14/765 , C07K2319/00 , C07K2319/30 , C07K2319/31 , C07K2319/735 , C12N15/62
摘要： The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.
-
公开(公告)号：EP1881850A1
公开(公告)日：2008-01-30
申请号：EP06759598.3
申请日：2006-05-11
发明人： ZHANG, Lianshan , VICK, Andrew, Mark , MILLICAN, Rohn, Lee, Junior , MAYER, John, Philip , GLAESNER, Wolfgang
IPC分类号： A61K47/48 , C07K14/605 , A61P3/10
CPC分类号： C07K14/605 , A61K47/60
摘要： The invention provides GLP-1 compounds coupled to two polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating conditions or disorders benefited by lowering blood glucose, decreasing food intake, decreasing gastric or intestinal emptying, increasing beta (ß) cell population, or decreasing gastric or intestinal motility.
-
公开(公告)号：EP1756156A1
公开(公告)日：2007-02-28
申请号：EP05755072.5
申请日：2005-05-19
发明人： BOKVIST, Bengt, Krister, Lilly Forschung GmbH , CUMMINS, Robert, Chadwick , GLAESNER, Wolfgang , GROMADA, Jesper, Lindgren, Lilly Forschung GmbH , MAYER, John, Philip , ZHANG, Lianshan , ALSINA-FERNANDEZ, Jorge
IPC分类号： C07K14/575
CPC分类号： C07K14/57563
摘要： The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
摘要翻译： 本发明包括选择性激活VPAC2受体并可用于治疗糖尿病的肽。
-
公开(公告)号：EP1735340A2
公开(公告)日：2006-12-27
申请号：EP05724363.6
申请日：2005-03-04
发明人： GLAESNER, Wolfgang , RATHNACHALAM, Radhakrishnan , MILLICAN, Rohn Lee, Jr. , TSCHANG, Sheng-Hung Rainbow
IPC分类号： C07K14/435
摘要： The invention provides FGF-21 compounds covalently attached to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active polypeptide with an extended elimination half-life and a slower clearance when compared to that of non-PEGylated polypeptide. These PEGylated FGF-21 compounds and compositions are useful in treating diabetes, obesity, and metabolic syndrome.
-
公开(公告)号：EP1605897A2
公开(公告)日：2005-12-21
申请号：EP04722142.9
申请日：2004-03-19
发明人： DIMARCHI, Richard, Dennis , GLAESNER, Wolfgang , MILLICAN, Rohn, Lee, Junior , VICK, Andrew, Mark , ZHANG, Lianshan
IPC分类号： A61K6/00
CPC分类号： C07K14/605 , A61K47/60
摘要： The invention provides GLP-1 compounds coupled to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active peptide with an extended half-life and a slower clearance when compared to that of unPEGylated peptide. These PEGylated GLP-1 compounds and compositions are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
-
公开(公告)号：EP1585959A2
公开(公告)日：2005-10-19
申请号：EP03700026.2
申请日：2003-01-03
IPC分类号： G01N1/00
CPC分类号： C07K14/605 , A61K38/00 , C07K2319/00
摘要： The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.
-
公开(公告)号：EP1355942A2
公开(公告)日：2003-10-29
申请号：EP01995845.3
申请日：2001-11-29
IPC分类号： C07K14/605 , C07K14/765 , C12N15/62 , A61K38/38 , A61K38/26 , C07K19/00 , A61P3/10
CPC分类号： C07H21/04 , A61K38/00 , C07K14/605 , C07K14/765 , C07K2319/00 , C07K2319/30 , C07K2319/31 , C07K2319/735 , C12N15/62
摘要： The present invention relates to glucagon-like-1 compounds fused to proteins that have the effect of extending the in vivo half-life of the peptides. These fusion proteins can be used to treat non-insulin dependent diabetes mellitus as well as a variety of other conditions.
摘要翻译： 本发明涉及与蛋白质融合的胰高血糖素样1化合物，其具有延长肽的体内半衰期的作用。 这些融合蛋白可用于治疗非胰岛素依赖性糖尿病以及各种其他病症。
-
公开(公告)号：EP1135493A2
公开(公告)日：2001-09-26
申请号：EP99967124.1
申请日：1999-11-23
发明人： BEALS, John, Michael , GLAESNER, Wolfgang , MICANOVIC, Radmilla , MILLICAN, Rohn, Lee, Jr. , WITCHER, Derrick, Ryan
IPC分类号： C12N15/12 , C12N1/21 , C07K14/505 , A61K47/48 , A61K38/18 , A01K67/027 , A61P7/06
CPC分类号： C07K14/505 , A01K2217/05 , A61K38/1816 , A61K47/60
摘要： The present invention addresses the need for better pharmaceutical agents for treating anemias by providing polymer derivatized non-glycosylated erythropoietic compounds which show stability and bioactivity in vivo. The invention further provides methods for preparing these derivatived proteins which involves the use of a linkerless aldehyde modification process.
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.027 秒)
